Perspectives
High-dose recombinant human erythropoietin for “low-risk” myelodysplastic patients: is more better?
Abstract
In present issue of the Journal Azzarà and Colleagues describe a retrospective series of 133 anemic patients with low/intermediate-1 risk myelodysplastic syndromes (MDS) treated with high-dose (40,000 IU twice a week) of alpha recombinant human erythropoietin (alpha-rHuEPO) (1).
